PRINCETON, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Novo Nordisk , a global healthcare company, today released its financial statement for the period January 1, 2007 to September 30, 2007.
Lars Rebien Sorensen, president and CEO, said “Our portfolio of modern insulins continues to show strong sales growth in all key markets. Within the next few months we will be launching Levemir(R) in FlexPen(R) in Japan, which will further support growth in the coming years.”
* For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.00 = DKK 5.54317.
Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems.In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk’s business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.
CONTACT: Media, Sean Clements, +1-609-514-8316; Investors, Christian Qvist
Frandsen, +1-609-919-7937
Web site: http://www.novonordisk.com/
http://www.novonordisk-us.com/
